drugset
drugset / Trial / NCT02873390

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

NCT02873390 ↗

Phase 1/2 Unknown 20 enrolled Ningbo Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.

Timeline

Start
2016-08
Primary completion
2018-03
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HerinCAR-PD1 cells Cell therapy 1e+07 cells/kg Intravenous
Subject HerinCAR-PD1 cells Cell therapy 5e+07 cells/kg Intravenous

Indications

cancer